<DOC>
	<DOCNO>NCT00192179</DOCNO>
	<brief_summary>A safety study compare , 7 day period , fever rate follow one dose either Influenza Virus Vaccine placebo administer outside influenza season healthy child adolescent age 6 less 18 year .</brief_summary>
	<brief_title>A Phase II , Trial Assess Safety Tolerability Influenza Virus Vaccine , CAIV-T Healthy Children Adolescents Ages 6 Less Than 18 Years .</brief_title>
	<detailed_description>This prospective , randomize , double-blind , placebo-controlled , study . Subjects randomize receive either CAIV-T Placebo . All subject healthy child adolescent age least 6 year age less 18 year age time enrollment .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>age 6 less 18 year time enrolment , female child bear potential use reliable method hormonal and/or nonhormonal contraception ( include cervical cap , diaphragm , condom , spermicide IUD ) sexual intercourse throughout entire study period ; provide negative pregnancy test ( detection limit less equal 25mL/ml ) 24 hour prior study vaccine administration agree avoid pregnancy participation study . N.B.lactating female exclude study . good health determine medical history , physical examination clinical judgement whose parent ( ) /legal guardian ( ) provide write informed consent nature study explain , along parent ( ) /legal guardian ( ) available completion study whose parent ( ) /legal guardian ( ) , reach study staff post vaccination contact ( telephone , clinic home visit ) along parent ( ) /legal guardian ( ) perceive unavailable difficult contact evaluation study visit study period serious chronic disease ( e.g . sign cardiac renal failure severe malnutrition ) include progressive neurological disease Down 's syndrome know cytogenetic disorder know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; cytotoxic agent receive blood product , include immunoglobulin , period six month prior vaccination conclusion study immunosuppressed immunocompromised individual living household document history hypersensitivity egg egg protein component CAIVT placebo history GuillainBarre Syndrome ( GBS ) intent administer investigational vaccine agent one month prior enrollment conclusion study , two week prior entry study , receive dose influenza treatment ( commercial investigational ) receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior enrollment use anticipate study , anytime prior study enrollment , receive influenza vaccine ( commercial investigational ) asthma require regular medical follow hospitalization precede year medical condition opinion investigator might interfere interpretation study result Note : Pregnancy person regular contact subject contraindication enrollment ongoing participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>